

Fish Health






- RTD
- SME
- ▲ Large enterprise
- ★ Association



IEO





HCMR

FCPCT

IRTA

UNIABDN

SARC

WP 24 Fish health - meagre

Lead P1 148.4 MM



HCMR

FCPCT

UNIABDN

IEO

ULL

WP 25 Fish health - greater amberjack MM

Lead P5 95.1



IMR


WP 26 Fish health - Atlantic halibut

Lead P7 4.16 MM



WP24 Fish health– meagre (*Argyrosomus regius*)

- Participants: HCMR, FCPCT, IRTA, UNIABDN, SARC




This WP will address bottlenecks relating to meagre health. Tasks include:

- (a) studies of key disease states
- (b) development of appropriate treatments
- (c) a first characterisation of the meagre immune system/ immune responses required for future immune intervention.



Specific objectives are:

1. Identify the causes of systemic granulomatosis and chronic ulcerative dermatopathy
2. Investigate anti-parasite treatments in juvenile meagre
3. Undertake preliminary characterisation of immune genes and study specific immune responses post-vaccination
4. Evaluate the occurrence of *Nocardia* infections in meagre and develop an autogenous vaccine
5. Develop diagnostic-prevention-treatment protocols for diseases in meagre.





Fish Health



HCMR:



1. Identify the causes of **systemic granulomatosis (SG)**, and **chronic ulcerative dermatopathy**
2. Evaluate the occurrence of **Nocardia** infections in meagre and develop an autogenous vaccine
3. Develop **diagnostic-prevention-treatment protocols** for diseases in meagre



Systemic granulomas



Chronic Ulcerative Dermatopathy




Systemic Granulomatosis



Feeding trials foreseen

trial #	Responsible	Factor to be assessed
1	HCMR	Vit D
2	HCMR	Ca/P
3	HCMR	Protein level
4	HCMR	Plant protein




Systemic Granulomatosis



Analysis to be conducted

- **Pathology**
 1. Macro/microscopical assessment
 2. Histology
 3. SEM/TEM, TEM-X-Ray microanalysis
 4. Blood biochemistry
 5. Biomarkers, Antioxidant Enzyme activity
- **Zootechnics**
 - Growth
 - Survival
 - Feed efficiency
 - Body composition




Chronic Ulcerative Dermatopathy

Rearing

- Rearing in natural sea water vs borehole
- Sampling of fish every 5-10 days (until visible lesions)
- Transfer in sea water (resolution of lesions)

Analysis will include


- Histology, histochemistry, gene expression
- Water chemistry



Nocardia infection (led by HCMR)



- Screen fish from various locations in Greece
- Isolate as many strains as possible
- Strain characterization and grouping (through metabolic profile, genetic analysis)
- Preparation of autogenous vaccine (inactivated bacterin)
- Toxicity testing in meagre



Diagnostic-recommendation manual for meager health (led by HCMR)

Participants HCMR, FCPCT, IRTA, UNIABDN

Results/findings from all tasks of WP24

Compilation in a pdf, uploaded in project's site





Fish Health



IRTA:



Task 24.3. Anti-parasitic treatments

D24.9 Determination of effective treatments for common monogenean parasites in meagre. Del date: month 48



Participants: IRTA

Use of monogenean parasites as a model

Try 4 to 6 products

In close collaboration with Culmarex to provide parasitized fish

This task should be started in 2015 but it can be moved according to the availability of juveniles.



Task 24.4. Nocardia infection in meagre

Subtask 24.4.1 Isolation and characterization of the pathogen



D24.4 Isolation and characterization of Nocardia from infected meagre.

Del date month 36

D24.6 Experimental vaccine for Nocardia for meagre.

Del date month 42

Participants HCMR, IRTA

Isolation of the parasite in collaboration with Culmarex (years 1 to 3)

Physiological characterization of the bacteria, for future vaccine design (years 1 to 4)



Task 24.4. Nocardia infection in meagre

Sub-task 24.4.2. Preparation of an autogenous vaccine

D24.10 Kinetics of antibody and cytokine production
established post-pathogen exposure or stimulation with
PAMPs. Del date month 48



Participants: IRTA, UNIABDN, HCMR

HCMR will develop the vaccine (year 4-5)

IRTA will carry out the challenge (year 4 for preparing challenge conditions and model and year 5 for the challenge itself)

Exchange of visits between IRTA and UNIABDN for using the PAMPs



Task 24.5. First characterisation of the immune system

D24.3 Cloning of key marker genes of innate and adaptive immune responses



Participants: UNIABDN, IRTA


IRTA will take samples of larvae and juveniles along years 1 and 2 and send them to UNIABDN

Exchange of visits for training in the use of PAMPs





(Note - Dotted lines are optional methodological approaches.)



Task 24.6. Monitor specific immune responses

D 24.10 Kinetics of antibody and cytokine production



Participants: IRTA, UNIABDN

Exchange of visits between partners after vaccination (years 3-4)

Use of a vaccine against *V. anguillarum* (commercial vaccine?)



UNIABDN:

Lead for Tasks 24.5
and 24.6



Jun Zou



Immune gene characterisation:

Clone RAG, Ig and TcR genes as markers of adaptive immunity

Clone IL-1, TNF, AMPs, IFN/Mx as markers of innate immunity

Clone cytokines of adaptive immunity as markers of Th responses




Antisera:

Develop anti-IgM and anti-IgT Abs to allow measurement of antibody responses

Monitor immune responses:

After vaccination with a bacterin (IRTA) in blood/mucus and in gill/kidney





Fish Health




FCPCT:




- Task 24.1. Systemic Granulomatosis.



- Subtask 24.1.1. Trial 4 .(FCPCT). Combined effect of vit. E, C and carotenoids
- Subtask 24.1.1. Trial 5. (FCPCT). Effect of Se, Mn and Fe
- Subtask 24.1.2. Health and pathological assessments. Histological studies from samples of trials 4&5, subtask 24.1.1



- Task 24.7. Description, diagnosis and treatment of other bacterial/viral infectious diseases (Led by FCPCT).
 - Monitoring the outbreak of diseases within the project
 - Susceptibility against *Vibrio*, *Photobacterium* and betanodavirus will be described
 - Establishment of treatment protocols with antibiotics (depending on the limitation of their use) for the pathogen isolated from natural outbreaks of diseases.



WP25 Fish Health-Greater Amberjack (*Seriola dumerili*)

- Participants: HCMR, FCPCT, UNIABDN, IEO, ULL



This WP will address bottlenecks relating to amberjack disease control. Tasks include:

- (a) dietary regimes that improve larval and adult disease resistance
- (b) diagnostic tests for several major pathogens, and
- (c) immune markers to aid selection of resistance, with a focus on mucosal defences.



Specific objectives are:

1. Provide early diagnosis tools for Epitheliocystis
2. Develop “antiparasite diets” to be used prior to sea cage culture
3. Begin characterisation of the immune system, with a focus on mucosal (skin/gill) defences
4. Develop anti-monogenean parasites infection rearing protocols
5. Develop diagnostic-prevention-treatment methods for diseases in greater amberjack



HCMR:



Task: Epitheliocystis in mesocosm reared amberjack

- Screening for epitheliocystis agents
- Diversity of “chlamydia” agents through phylogenetic analysis
- Develop specific molecular probes for early detection
- Validation of tool in larval rearing trials



ABDN:

Identify immune markers of mucosal defences



Clone IL-17, IL-22, iNOS, AMPs and IgT

Study their modulation at mucosal sites during:

- 1) In vitro using gill cultures
- 2) In vivo following different diet regimes and during development






Fish Health




FCPCT:



- Task 25.2. Promoting resistance to parasitic incidence (led by FCPCT).
 - Use of mucus stimulation products (MOS, beta-glucans or phytobiotics) during early on-growing.
 - Providing samples for Task 25.3
 - Resistance to monogenean infection by cohabitation
 - Morphometric and ultrastructure studies of target tissues (i.e. gills and skin)



- Task 25.5. Description, diagnosis and treatment of other bacterial/viral infectious diseases (Led by FCPCT).
 - Monitoring the outbreak of diseases within the project
 - Susceptibility against *Vibrio*, *Photobacterium* and betanodavirus will be described
 - Establishment of treatment protocols with antibiotics (depending on the limitation of their use) for the pathogen isolated from natural outbreaks of diseases.





IEO/ ULL:



Task 25.4: Effectiveness of stocking density and anti-oncomiracidia attaching substances in the control of monogenean parasites. **Rearing site: IEO**

Deliverables:

D25.6 Rearing protocol against monogenean parasites. The efficacy of the bath lectin treatment will be assessed at two densities for survival, growth and fish health (plasma analysis of triglycerides, cholesterol, protein, enzymes, cortisol, glucose, lactate, osmolality, electrolytes) and physiology (viability and integrity of skin cells and osmorregulatory epithelia: gills and gut ATPase activity).

Results will be related with the presence and density of parasites in experimental tanks, that will be estimated throughout periodical monitoring of collectors devices for eggs and fish sampling for adult parasites. **Month 57 (starting from Yr 2)**



Leader: IEO; **participants,** ULL

Exchange of samples and techniques

IEO will provide samples of skin, gills and gut to ULL

Exchange of visits for training

No visit scheduled

WP26 Fish health– Atlantic halibut (*Hippoglossus hippoglossus*)

- Participants: IMR



Researchers: Sonal Patel and Audun H. Nerland



This WP will address a key bottleneck relating to Atlantic halibut larval health, namely **nodavirus** (Viral Neural Necrosis, VNN) outbreaks in larval and juvenile stages. Tasks include:


- (a) production of the VNN capsid protein in *E. coli*, tobacco plants and possibly microalgae
- (b) oral delivery of the recombinant capsid protein in *Artemia* to late larval stages
- (c) assessment of the degree of protection obtained with the different formulations, assessed by histology and immunohistochemistry with antibodies to NVV.



Specific objective is:

To determine the effect of delivering recombinant capsid protein during late larval stages on protection to **nodavirus** (VNN)

Will liaise closely with the TargetFish programme (EU 7th FP) – details to be discussed with co-ordinator of Targetfish programme



WP26 – Atlantic halibut: Tasks

Plan:



1. Capsid protein expression → 2. Delivery → 3. Challenge with Nodavirus

Expression of nodavirus capsid protein (E. coli, tobacco plant and protozoa)

Expression in tobacco plants



Glycosylation




WP26 – Atlantic halibut: Tasks

Plan:

1. Capsid protein expression → 2. **Delivery** → 3. Challenge with Nodavirus

Delivery to late larval stages and juveniles






WP26 – Atlantic halibut: Tasks

Plan:

1. Capsid protein expression → 2. Delivery → 3. Challenge with Nodavirus

Challenge

1. Mortality
2. Immune response



WP 24 deliverables

D24.1 The effect of vitamin D inclusions in diets in the development of Systemic Granulomatosis in meagre (HCMR)

D24.2 The effect of Ca/P ratio in the diet in the development of Systemic Granulomatosis in meagre (HCMR)

D24.3 Cloning of key marker genes of innate & adaptive immune responses in meagre (ABDN)


D24.4 Isolation and characterization of Nocardia from infected meagre (HCMR)

D24.5 The effect of high plant protein diets in the development of Systemic Granulomatosis in meagre (HCMR)

D24.6 Experimental vaccine for Nocardia for meagre (HCMR)

D24.7 Diagnostics protocol for Chronic Ulcerative Dermatopathy in meagre (HCMR)

D24.8 Report on the prevention/treatment of Chronic Ulcerative Dermatopathy in meagre (HCMR)



WP 24 deliverables

- D24.9** Determination of effective treatments for common monogenean parasites in meagre (IRTA)
- D24.10** Kinetics of antibody and cytokine production established post-pathogen exposure or stimulation with PAMPs (ABDN)
- D24.11** Recommended levels of pro- and anti-oxidant nutrients to prevent Systemic Granulomatosis in meagre (FCPCT)
- D24.12** Determination of efficacy of vaccination of meagre against Nocardia (IRTA)
- D24.13** Description of immune gene expression pre- and post-immunization of meagre with Nocardia (IRTA)
- D24.14** Diagnostics protocol for Systemic Granulomatosis, causes and solutions in meagre (HCMR)
- D24.15** Report on the prevention/treatment of Systemic Granulomatosis in meagre (HCMR)
- D24.16** Report of the major bacterial and viral diseases found in meagre, and where useful treatments have been developed, complete protocols for their implementation by the industry will be provided (FCPCT)
- D24.17** Diagnostic-recommendation manual for meagre fish health (HCMR)



WP 25 deliverables

- D25.1** Marker genes of mucosal immunity in greater amberjack cloned and ways to increase their expression level determined (ABDN)
- D25.2** Mucus defences of greater amberjack analysed and immune potential characterised (**not HCMR !!!!**)
- D25.3** Impact of dietary regime on parasite resistance and mucosal defences of greater amberjack juveniles (ABDN)
- D25.4** Protocol for early diagnosis of epitheliocystis during early stages of greater amberjack culture (HCMR)
- D25.5** Impact of oral administration of greater amberjack with mucus stimulation products on immune resistance to parasitic infections and development of molecular markers for its evaluation (FCPCT)
- D25.6** Rearing protocol against monogenean parasites (IEO)
- D25.7** Report on the major bacterial and viral diseases found in greater amberjack, and where useful treatments have been developed, complete protocols for their implementation by the industry will be provided (FCPCT)
- D25.8** Diagnostic-recommendation manual for greater amberjack fish health (HCMR)

WP 26 deliverables

D26.1 Assess the use of two eukaryotic expression systems; microalgae and a protozoa (*Leishmania tarentolae*) for production of nodavirus capsid protein (IMR)

D26.2 Testing of the delivery of vaccine candidates through Artemia to Atlantic halibut larvae (IMR)

D26.3 Determine immune response and effectiveness of orally delivered VNN capsid protein on protection of Atlantic halibut larvae (IMR)





Fish Health



MS Number	Description	Delivery date
51	Design of primers for amplification of meagre target gene DNA sequences	12
52	Grow-out of larvae and collection of samples from immune ontogeny time-line	24
53	Amplification and sequencing of target gene sequences from stimulated tissues	30
54	Completion of challenge and collection of samples for study of immune gene modulation	36
55	Complete preparation of cDNA synthesis from all meagre samples	40
56	Complete gene expression analysis for immune ontogeny	42
57	Complete gene expression analysis for immune stimulus /response	45